The Case Against GLP-1 Agonists

You’ve likely heard the headlines: the new class of GLP-1 agonist drugs with silly names such as Wegovy, Ozempic, Saxenda, Rybelsus, and Mounjaro are flying off the shelves so fast that pharmacies are running out. Originally intended to reduce blood glucose in people with type 2 diabetes, it was observed that people taking these drugs lost weight, sometimes a substantial quantity. Human clinical trials have since corroborated these weight loss effects. If you have been following this a...